Kazia To Present DIPG Data At ISPNO June 29 - July 2
Portfolio Pulse from Benzinga Newsdesk
Kazia Therapeutics Limited (NASDAQ:KZIA) will present new data from its lead program, paxalisib, at the 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) from June 29 to July 2, 2024. Additionally, an article in the European Journal of Cancer highlights the need for mutation-specific, CNS-penetrant inhibitors to treat pediatric patients with Diffuse Midline Glioma (DMG).
June 27, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kazia Therapeutics will present new data on its lead program, paxalisib, at ISPNO 2024, and has published an article in the European Journal of Cancer emphasizing the need for mutation-specific inhibitors for pediatric DMG.
The presentation of new data at a major symposium and the publication in a reputable journal are likely to positively impact investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100